David Barnes of Zeneca Group: Prescription for growth - The precocious, three-year-old U.K. drug company has outgrown its parent, doubled profits and won over onceskeptical investors. Its CEO tells how.
Year of publication:
Institutional investor. - New York, NY : Institutional Investor Inc., ISSN 0192-5660, ZDB-ID 3955412. - Vol. 21.1996, 4, p. 29-31